An artificial intelligence-powered precision cardiovascular medicine company named Cardio Diagnostics has launched a first-of-its-kind platform called Actionable Clinical Intelligence or ACI, that offers new epigenetic and genetic insights to clinicians prescribing the company’s Epi+Gen CHD and PrecisionCHD tests.
Epi+Gen CHD is a powerful test that predicts the three-year risk for a coronary heart disease (CHD) event – a heart attack – and PrecisionCHD is a test for the detection of CHD. These AI-powered integrated genetic-epigenetic clinical tests only require a simple blood draw that can be performed at home or in provider settings without the need to wait weeks or months to get tested.
